GLP1减重宝典·2026-01-19 12:14Core Viewpoint - GLP-1 (Glucagon-like peptide-1) plays a crucial role in regulating blood sugar and controlling weight, with significant advancements in the development of GLP-1 drugs globally, particularly focusing on Semaglutide and Tirzepatide [2][4]. Group 1: GLP-1 Drug Overview - GLP-1 is secreted by intestinal L cells and is important for slowing gastric motility, prolonging gastric emptying, and effectively suppressing appetite [2]. - Notable GLP-1 drugs include Semaglutide from Novo Nordisk, with its formulations being Ozempic (for diabetes), Wegovy (for weight loss), and Rybelsus (oral version) [2][9]. - Tirzepatide from Eli Lilly, marketed as Mounjaro, is also gaining attention for its dual action in glucose control and weight loss [2]. Group 2: Oral Semaglutide (Rybelsus) Advantages - Rybelsus is the first and only oral GLP-1 receptor agonist available globally, offering convenience such as no refrigeration and ease of transport, which enhances patient adherence [4][6]. - The formulation includes Semaglutide and an absorption enhancer, SNAC, which increases the drug's bioavailability by approximately 100 times [6]. Group 3: Clinical Research and Efficacy - The global Phase III clinical study PIONEER involved 11,505 patients and confirmed the efficacy and safety of oral Semaglutide, showing significant reductions in blood sugar and weight [8]. - In China, newly diagnosed type 2 diabetes patients achieved a HbA1c target rate of 92.3% with Rybelsus monotherapy [8]. - The STEP studies demonstrated that weekly injections of 2.4 mg Semaglutide resulted in an average weight loss of 15% in obese patients, showcasing its effectiveness compared to other weight loss medications [11]. Group 4: Comparison of Different Formulations - Ozempic is an injectable diabetes medication, Wegovy is an injectable weight loss drug, and Rybelsus is an oral diabetes medication [9][10]. - Oral Semaglutide can potentially replace injectable forms without dosage adjustments, providing a "pain-free" weight loss option [13]. - However, achieving similar weight loss effects with oral Semaglutide may require higher doses, which are currently limited to 14 mg per day [15]. Group 5: Safety and Tolerability - Clinical trials indicate that oral Semaglutide maintains good safety and tolerability, although higher doses may lead to adverse effects not seen with injectable forms [15][18]. - The latest OASIS 4 study showed that patients on 25 mg oral Semaglutide lost an average of 13.6% of their body weight over 64 weeks, with potential for even greater loss if all participants completed the treatment [17]. Group 6: Patient Considerations - Oral Semaglutide offers advantages in convenience and patient acceptance, but patients should consult healthcare providers to consider personal needs and tolerability [18].